Is Gilteritinib too expensive among similar targeted drugs?

Giritinib (Gilteritinib, trade name Xospata) is a FLT3 inhibitor, mainly used to treat FLT3 Patients with mutation-positive relapsed or refractory acute myeloid leukemia (AML). As an oral targeted drug, it can precisely inhibit abnormal signaling pathways and significantly improve the remission rate and survival period of some patients. It is currently one of the important personalized treatment options for this population.

Among the same kind of FLT3 targeted drugs, midostaurin (Midostaurin) and Quizartinib (Quizartinib) are also common. Generally speaking, the prices of these drugs are generally high, but the price of gilitinib is in the "mid-to-high range". For example, the monthly treatment cost of imported original research giritinib often reaches tens of thousands of yuan, but after midostaurin has been included in domestic medical insurance, patients' out-of-pocket burden is relatively lower. Therefore, from the perspective of patient affordability, giritinib does appear to be more expensive.

There are three main reasons for the high price of giritinib: First, its research and development costs are high and the market patient group is relatively small, resulting in a high unit price; second, as a new generation of more selective FLT3 inhibitors, its efficacy and tolerability are better than some previous-generation drugs; third, it has not yet been widely included in medical insurance in China, resulting in a lack of reimbursement channels for patients and greater actual payment pressure.

To sum up, the price of giritinib is indeed high among similar drugs, but its efficacy advantages still make it a priority for many doctors and patients. If the financial burden is heavy, you can pay attention to the dynamic adjustments of medical insurance policies, or consult formal channels for assistance projects. In the future, as more similar drugs enter the market and medical insurance negotiations advance, the price of giritinib is expected to gradually decrease, making it truly affordable and accessible to more patients.

Reference materials:https://www.drugs.com/